GlassScriptPhysician profile
Andreana L Hodgini
NPI 1821033317
$8,804.92
in general payments reported to CMS, 2019-2025
49 companies · $16.49 in 2025
The $16.49 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,057 · 2020: $1,170 · 2021: $2,142 · 2022: $1,969 · 2023: $1,771 · 2024: $680 · 2025: $16.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,466.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,330.04 | 2019-2024 | |
| Novo Nordisk INC | $966.56 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Supernus Pharmaceuticals, INC. | $722.32 | 2021-2024 | Qelbree, Qelbree |
| Lilly USA, LLC | $606.82 | 2019-2024 | Mounjaro, Emgality, Reyvow |
| Astrazeneca Pharmaceuticals LP | $559.33 | 2019-2024 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $469.60 | 2021-2023 | |
| Glaxosmithkline, LLC. | $429.11 | 2019-2023 | Trelegy Ellipta |
| Amgen INC. | $368.43 | 2019-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $298.55 | 2019-2024 | Xifaxan |
| Pfizer INC. | $267.53 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.84 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $212.23 | 2019-2023 | Trintellix |
| Allergan, INC. | $200.76 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $188.74 | 2019-2023 | Spravato |
| Corium, LLC | $161.94 | 2022-2024 | Azstarys |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andreana Hodgini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.